Short-term kidney transplantation outcomes have improved significantly over the past decades with the implementation of induction therapies and calcineurin inhibitor (CNI)--based immunosuppression regimens.^[@R1],[@R2]^ While these treatments reduce episodes of acute cellular rejection, they have failed to improve long-term allograft survival, with only 50%--60% of allografts functioning after 10 years.^[@R3]-[@R6]^ The reasons for long-term allograft failure are multifactorial, but development of de novo donor-specific anti--human leukocyte antigen (HLA) antibodies (dnDSAs) is recognized as a leading cause, affecting up to 30% of unsensitized kidney transplant recipients,^[@R7],[@R8]^ with 1%--10% occurring within the first year posttransplant.^[@R9]-[@R15]^

DSA-positive recipients (DSA^POS^) are at increased risk of antibody-mediated rejection (AMR), a condition that can lead to accelerated allograft failure and for which treatment strategies are still not standardized.^[@R11]^ Highly sensitized patients with pretransplant DSA incur a substantially higher rate of AMR than their DSA-negative counterparts. However, predicting which unsensitized recipients will develop dnDSA, and of those which will suffer AMR, remains difficult.^[@R7],[@R12],[@R16]-[@R19]^ Recent studies suggest that the ability of DSA to activate the complement cascade,^[@R20]^ assessed via C1q- or C3d-binding assays, correlates with allograft loss and can help risk-stratify DSA^POS^ recipients.^[@R21]-[@R28]^ However, data about the utility of these measures in clinical practice have not been consistent thus far.^[@R29]-[@R32]^

Memory B cells are formed within germinal centers following the primary encounter with alloantigen and are able to generate an accelerated immune response upon antigen re-encounter.^[@R33]-[@R36]^ Memory B cells are also detectable in the peripheral blood of highly sensitized recipients before and during an AMR episode, even in the absence of circulating DSA.^[@R37],[@R38]^ However, no study to date has comprehensively looked at the immune phenotype of immunologically naive transplant recipients to investigate whether other immunologic perturbations precede antibody development or AMR.

One reason for the lack of comprehensive immune phenotyping of transplant patients is that standard flow cytometry is limited in the number of markers that can be probed in a single experiment due to autofluorescence and spectral spillover associated with fluorophores. Time-of-flight mass cytometry (CyTOF) utilizes metal isotopes that possess unique mass spectrometry signatures enabling the analysis of up to 50 cellular markers at the same time. Furthermore, CyTOF reduces experimental variability as metal isotopes can be used to tag samples with barcodes, allowing multiple samples to be analyzed simultaneously. We used CyTOF to test the hypothesis that changes occur in the phenotype of circulating T and/or B cells before the development of DSA or AMR. To do this, we comprehensively analyzed immune phenotypes of prospectively collected peripheral blood mononuclear cells (PBMC) from pediatric kidney transplant recipients who did or did not develop dnDSA, with or without AMR.

MATERIALS AND METHODS
=====================

Subjects and Sample Collection
------------------------------

Pediatric subjects (\<18 y at the time of transplant) transplanted at Gaslini Hospital in Genoa, Italy, between August 2003 and March 2013 underwent serial measurement of circulating DSA at months 1, 2, 6, 9, 12 posttransplant, and every 6 months thereafter. At the time of each DSA measurement, patients also had PBMC collected and stored in liquid nitrogen. During the study period, 136 kidney transplants were consecutively performed.

Patients were included in this study if they were recipients of a first kidney graft and nonsensitized (Panel-reactive antibody = 0; absence of any HLA antibody (Ab) in historical sera tested before kidney transplant; n = 98). We performed a case-control study, where we analyzed serially collected PBMC aliquots at 2 months posttransplant, at the last available visit before DSA development, and at the time of first DSA detection in all the consecutive patients who developed DSA within the first 12 months after transplant (n = 10) and 11 patients who received a kidney transplant during the same time period (±6 mo) at the same institution but did not develop DSA during the same follow-up time posttransplant. Demographic and clinical characteristics of donors and recipients were collected up to 6 years posttransplant. The protocol has been approved by the Gaslini Hospital Institutional Review Board (IRB 867/2014).

Patient Treatment and Management
--------------------------------

All kidney transplant recipients received the same immunosuppressive therapy consisting of anti-CD25 antibody induction (basiliximab) and maintenance with mycophenolate mofetil and a CNI (either tacrolimus or cyclosporine) with or without steroids. Tacrolimus target trough levels were 8--10 ng/mL in the first month posttransplant, 7--9 ng/mL from months 2--3, and 6--8 ng/mL thereafter. Two-hour postdose target levels of cyclosporine in whole blood (C~2~) were 1400--1800 ng/mL in the first month posttransplant, 1200--1600 ng/mL in the second month, 1000--1400 from months 3--6, and 800--1200 thereafter (see adherence calculations in section below). Graft biopsies were performed as per clinical indication, including DSA development. Diagnosis of AMR was based on Banff 2013.^[@R39]^

Detection and Characterization of HLA Abs
-----------------------------------------

HLA classes I and II typing were performed as described previously.^[@R21],[@R40]^ Anti--HLA classes I and II IgG Abs were tested with a bead--based detection assay. We used the LABScreen Mixed kit (One Lambda; Thermo Fisher Scientific, Waltham, MA), which simultaneously detects classes I and II Abs, and the single antigen bead assays (Single Antigen kit, One Lambda; Thermo Fisher Scientific) to identify HLA classes I and II specificities.^[@R40]^ Before testing, all sera were pretreated with disodium EDTA (final concentration 10 mM, pH 7.4; Sigma--Aldrich, Milan, Italy) to rule out underestimation of Ab mean fluorescence intensity (MFI) strength due to the prozone phenomenon.^[@R41]^ Screening assay results above a cutoff value of 3.0 for the ratio of sample to negative control were considered positive. Single--antigen results above an MFI cutoff value of 1000 were considered positive.

Heat--inactivated patient sera were tested with C1qScreen (One Lambda; Thermo Fisher Scientific) for identification of complement--binding Abs, as described.^[@R27]^ Ab positivity was assigned at \>500 MFI. Serum samples were analyzed in a blinded fashion for the presence of C3d--binding DSAs with the single--antigen flow bead technology, according to the manufacturer's protocol (Immucor Lifecode Transplant Diagnostics, Nijlen, Belgium).^[@R26]^

Adherence to CNI Therapy
------------------------

Routine laboratory measurement of 2-hour postdose cyclosporine (C~2~) levels and tacrolimus trough levels in whole blood were determined using an antibody-conjugated magnetic immunoassay method and by microparticle enzyme immunoassay based on the Abbott IMx (Abbott Laboratories, Abbott Park, IL), respectively.

Tacrolimus and cyclosporine C~2~ levels were collected over a period of \>1 year. Intrapatient variability (IPV) has been shown to be a useful surrogate for CNI adherence and a predictor of long-term kidney transplant outcomes.^[@R42]-[@R44]^ Given the small sample size of our cohort, CNI IPV was described by the coefficient of variation (CV%) and calculated as the square root of the ratio of the variance to the mean, ![](txd-5-e481-i001.jpg), which has been shown to provide an accurate estimate for these studies.^[@R42]^ Only levels collected after 6 months posttransplant, when dosing is assumed to be stable, were included in IPV calculations.

CyTOF Sample Preparation
------------------------

Our aim was to map the peripheral blood immune system of renal transplant recipients and its evolution over time, while minimizing batch effect, to increase our ability to capture differences in frequencies of immune cell compartments. To do this, we barcoded samples collected from the same recipients at the 3 different time points with anti-CD45 antibodies conjugated to unique metal isotopes before pooling the samples together. CyTOF sample preparation was conducted as previously reported.^[@R45],[@R46]^ Antibodies were either purchased preconjugated from Fluidigm (formerly DVS Sciences) or purchased purified and conjugated in-house using MaxPar X8 Polymer Kits (Fluidigm) according to the manufacturer's instructions. Sixty-three samples (21 recipients with approximately 3 time points each) were processed in 4 separate batches using 4 barcoding antibodies for each sample (to denote patient and time point) and pooled together (Figure [1](#F1){ref-type="fig"}). All PBMC were stained with a panel of 35 antibodies (34 for clustering, 1 for viability; see **Table S1, SDC**, <http://links.lww.com/TXD/A217>).

![Study design. Blood was collected from pediatric transplant recipients every 2--3 mo to monitor DSA formation. Peripheral blood mononuclear cells (PBMC) were isolated from samples taken at 2 mo posttransplant, at the time DSA detection, and the sample just before DSA detection (corresponding time points were used for DSA^NEG^ recipients). Cells were barcoded for patient and time, pooled, and stained with 35 antibodies conjugated to unique metal isotopes. Single-cell data acquired from time-of-flight mass cytometry (CyTOF) were clustered using Phenograph to identify cell clusters and how they evolved over time in each patient (see Materials and Methods). DSA, donor-specific antibody; DSA^NEG^, DSA-negative recipients; DSA^P^OS, DSA-positive recipients; FCS, flow cytometry standard; post-tx, post-transplant; tSNE, t-distributed stochastic neighbor embedding. J Gregory \@2018 printed with the permission of Mount Sinai Health System.](txd-5-e481-g001){#F1}

CyTOF Data Acquisition
----------------------

CyTOF data were acquired at Icahn School of Medicine at Mount Sinai as previously reported by others.^[@R45],[@R46]^ Samples were suspended in deionized water containing a 1/20 dilution of EQ 4 Element Beads (Fluidigm) at a concentration of 1 million cells/mL and acquired on a CyTOF2 (Fluidigm) equipped with a SuperSampler fluidics system (Victorian Airships) at an event rate of \<500 events/s. After acquisition, the data were normalized using bead-based normalization in the CyTOF software. Barcodes were demultiplexed using the Fluidigm debarcoding software. The data were gated to exclude residual normalization beads, debris, dead cells, and doublets, leaving live CD45^+^ events for subsequent clustering and high-dimensional analyses.

CyTOF Data Analysis
-------------------

We utilized a CyTOF analysis pipeline that was previously established in our laboratory.^[@R46]^ We first clustered cells using the Phenograph algorithm^[@R47]^ and then curated the metaclusters obtained. The frequencies for each common population were obtained by summation of the frequencies in each metacluster and subsequently debarcoded to obtain frequencies for each time point and patient. To minimize variability in measurement, our analysis strategy was structured as follows:

1.  Application of Phenograph to computationally pooled samples: we pooled in silico all labeled cells from all time points for each patient to analyze the major immune compartments (10 000 cells per time point for an average of 30 000 cells per patient); we applied Phenograph and then demultiplexed them. This allowed us to map the same subsets in all the samples, as opposed to gating each sample for each patient individually.

2.  Equal contribution of the samples: to avoid bias in Phenograph for the subsets present in the samples with a greater total number of T or B cells, we sampled 500 cells per sample for the CD4^+^ and CD8^+^ T cell subclustering. For the B-cell compartment, not all samples had 500 cells. For the 5 recipients who had at least 1 PBMC sample with \<500 B cells, we adjusted the contribution of cells to maximize the number of B cells analyzed. In this way, we were able to minimize clustering bias while maintaining equal contribution from each sample.

3.  Reiteration: to increase power of the analyses for the cell subsets with low number of events, we reiterated the entirety of the B-cell sampling process and Phenograph clustering up to 5 times to achieve robustness in the results. Through our strategy, we effectively analyzed up to 2500 cells per sample. Despite the level of stringency imposed by the repeated sampling and clustering process, we observed little dispersion in the results indicating that our findings were robust (CV of 5% for cells with an antibody-secreting phenotype and 12% for cells with a memory B phenotype). We did not observe significant differences in the average and SD of the signal for each marker nor in the frequencies of the major immune compartments across repeated analyses.

Statistical Analyses
--------------------

Statistical significance was performed using GraphPad Prism or R. Statistical tests used are reported in the figure legends. Comparisons between DSA^POS^, DSA-negative recipients (DSA^NEG^), and DSA^POS^AMR-positive recipients (AMRPOS) groups at the same time point were performed by unpaired *t* tests or ANOVA (nonparametric tests were also performed yielding similar results). Differences are considered significant at *P* \< 0.05.

RESULTS
=======

Recipients
----------

All included subjects were unsensitized, first-time pediatric recipients of kidney transplants who received the same induction and similar immunosuppression therapy (Table [1](#T1){ref-type="table"}). Adherence to CNI maintenance immunosuppression, as determined by cyclosporine or tacrolimus IPV at 6 months posttransplant and onward, did not differ in DSA^POS^ versus DSA^NEG^ recipients or in DSA^POS^ patients who developed (DSA^POS^AMR^POS^) or not (DSA^POS^AMR-negative recipients (AMR^NEG^)) AMR (**Figure S1, SDC**, <http://links.lww.com/TXD/A217>, see Adherence to CNI Therapy in the Materials and Methods section). The majority of patients received deceased donor renal transplants (Table [1](#T1){ref-type="table"}). Ten recipients developed DSA posttransplant, and 11 remained DSA negative over the 5-year follow-up period. Baseline characteristics did not differ significantly between DSA^POS^ and DSA^NEG^ recipients (Table [1](#T1){ref-type="table"}). Recipients who developed DSA had increased rates of acute cellular rejection, AMR, and graft loss during the 4-year follow-up period (Table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics of donors and recipients

![](txd-5-e481-g002)

###### 

Allograft outcomes of patients by DSA status

![](txd-5-e481-g003)

DSA Antibody Levels and C1q and C3d Binding
-------------------------------------------

Baseline characteristics (**Table S2, SDC**, <http://links.lww.com/TXD/A217>) of MFI levels at the time of DSA detection (9.5 ± 3.4 mo posttransplant) were similar between recipients who did and did not develop AMR (**Table S3, SDC**, <http://links.lww.com/TXD/A217>; 13 686.6 ± 9300.8 vs 11 375.4 ± 4234.5, respectively; *P* = 0.63). All DSA^POS^ patients developed antibodies reactive against HLA class II antigens. Three recipients also had DSA against HLA class I, but those antibodies were developed either at the time of DSA detection (n = 1) or after the onset of class II DSA (n = 2; **Table S3, SDC**, <http://links.lww.com/TXD/A217>). DSA levels remained generally stable over time, except in 3 DSA^POS^AMR^POS^ patients who showed an increase in their levels.

The majority of DSAs were targeted against HLA-DQ and bound C1q (Table [3](#T3){ref-type="table"}). Three of the 5 DSA^POS^AMR^POS^ recipients had DSA that bound C3d upon initial DSA detection, while only 1 DSA^POS^AMR^NEG^ recipient had C3d-binding DSA (Table [3](#T3){ref-type="table"}).

###### 

DSA specificities for DSA^POS^ recipients

![](txd-5-e481-g004)

Frequencies of Major Immune Compartments
----------------------------------------

We analyzed the evolution of 9 major immune compartments in peripheral blood (Figure [2](#F2){ref-type="fig"}) using an unbiased algorithm (Phenograph^[@R49]^; see Materials and Methods section). The resultant high-dimensional clustered data were visualized in 2 dimensions with preserved single-cell resolution using viSNE (Figure [2](#F2){ref-type="fig"}A). Once all clusters were defined as belonging to a major immune compartment, the cellular frequencies were calculated for each patient at all time points.

![Frequencies of major immune compartments. A, Representative viSNE plots of peripheral blood mononuclear cells (PBMC) colored by their relative expression of cell markers used to define major immune clusters (populations defined on the right). B, Percentages of major immune compartments based on the summation of Phenograph clusters (see Materials and Methods, n = 21 subjects). Error bars represent SEM. Comparisons between DSA^POS^ and DSA^NEG^ (\**P* \< 0.05, \*\**P* \< 0.01 by unpaired *t* test) and with baseline (▴*P* \< 0.05 by paired *t* test). DC, Dendritic Cells; DSA, donor-specific antibody; DSA^NEG^, DSA-negative recipients; DSA^POS^, DSA-positive recipients; NK, Natural Killer; pDC, Plasmacytoid Dendritic Cells; SEM, standard error of the mean.](txd-5-e481-g005){#F2}

Overall, cell frequencies of major immune compartments remained relatively stable throughout the 3 time points and were similar to the cell frequencies previously reported by our group in adult kidney transplant recipients during the first year after transplantation.^[@R46]^ Major immune subsets were not significantly different between DSA^POS^ and DSA^NEG^ recipients except for monocytes, which were elevated in DSA^POS^ recipients before DSA detection (Figure [2](#F2){ref-type="fig"}). While no single cluster reciprocally increased in the DSA^NEG^ group, an increase in several lymphocyte populations in DSA^NEG^ recipients collectively accounted for the elevated monocytes in DSA^POS^ recipients before DSA development (**Figure S2, SDC**, <http://links.lww.com/TXD/A217>). B cells declined over time in both groups, but only DSA^NEG^ subjects had a statistically significant decrease in total B cells from 2 months posttransplant to the time of DSA detection.

DSA^POS^ and DSA^NEG^ Recipients Have Similar Frequencies of Circulating CD4^+^ and CD8^+^ T-Cell Subsets
---------------------------------------------------------------------------------------------------------

Although we did not detect any significant differences between CD4^+^ or CD8^+^ T cells in DSA^POS^ versus DSA^NEG^ recipients (Figure [2](#F2){ref-type="fig"}), we performed a second level of unbiased clustering within those compartments using 20 additional markers to determine whether any subpopulations differed between the 2 recipient groups (**Table S1, SDC**, <http://links.lww.com/TXD/A217>; Figure [3](#F3){ref-type="fig"}A and B). The cells from all recipients were pooled together, and 8 CD4^+^ (Figure [3](#F3){ref-type="fig"}A and B) and 7 CD8^+^ (Figure [4](#F4){ref-type="fig"}A and B) T-cell subpopulations were defined based on relative expression of the clustering markers. The subclusters were then demultiplexed to extract the frequency of each subpopulation for each patient over time (Figures [3](#F3){ref-type="fig"}B and [4](#F4){ref-type="fig"}B). Similar to our findings for the major immune compartments, no significant differences in CD4^+^ and CD8^+^ T-cell subpopulations were detected.

![CD4^+^ T-cell subpopulations did not differ between DSA^POS^ and DSA^NEG^ recipients. A, viSNE analysis of CD3^+^CD4^+^ T-cell subpopulations (top) labeled by Phenograph clustering analysis and corresponding heatmap assignment (bottom) for all subjects and time points combined (see Materials and Methods). B, Analysis of the percentages of 8 CD4^+^ subpopulations (see Materials and Methods, n = 21 subjects). Error bars represent SEM. Comparisons at all time points were not significantly different (unpaired *t* test). CM, Central Memory; DSA, donor-specific antibody; DSA^NEG^, DSA-negative recipients; DSA^POS^, DSA-positive recipients; PBMC, peripheral blood mononuclear cells; SEM, standard error of the mean; T~FH~, T-follicular helper-like; T~REG~, regulatory T cells.](txd-5-e481-g006){#F3}

![CD8^+^ T-cell subpopulations did not differ between DSA^POS^ and DSA^NEG^ recipients. A, viSNE analysis of CD3^+^CD8^+^ T cell subpopulations (top) labeled by Phenograph clustering analysis and corresponding heatmap assignment (bottom) for all subjects and time points combined (see Materials and Methods). B, Analysis of the percentages of 7 CD8^+^ subpopulations (see Materials and Methods, n = 21 subjects). Error bars represent SEM. Comparisons at all time points were not significantly different (unpaired *t* test). CM, Central Memory; DSA, donor-specific antibody; DSA^NEG^, DSA-negative recipients; DSA^POS^, DSA-positive recipients; PBMC, peripheral blood mononuclear cells; SEM, standard error of the mean.](txd-5-e481-g007){#F4}

Of note, CD4^+^ T cells with a T-follicular helper-like (T~FH~) phenotype (see Figure [3](#F3){ref-type="fig"}, clusters 2, 11, and 19 for markers) were not increased in the peripheral circulation of DSA^POS^ recipients despite their importance in antibody production.^[@R50],[@R51]^ The percentages of regulatory T cells (T~REG~) also did also not significantly differ between DSA^POS^ and DSA^NEG^ recipients at the analyzed time points. When we stratified DSA^POS^ recipients according to the future development of AMR, we could not detect any significant differences in any of the CD4^+^ or CD8^+^ T-cell compartments (not shown).

B Cells With Antibody-Secreting and Memory Phenotypes Are Increased in DSA^POS^ Recipients Before AMR Development
-----------------------------------------------------------------------------------------------------------------

Within the B-cell compartment, we identified 10 distinct B-cell subpopulations, including B cells with a naive (IgD^+^CD27^−^),^[@R52]^ regulatory (CD25^hi^),^[@R53],[@R54]^ antibody-secreting (IgD^−^CD27^+^CD38^+^),^[@R55]^ and memory (IgD^−^CD27^+^CD38^−^)^[@R52]^ phenotype. We did not detect statistically significant differences at any time point in B-cell subpopulations between DSA^POS^ and DSA^NEG^ recipients (Figure [5](#F5){ref-type="fig"}B).

![B-cell subpopulations were similar in DSA^POS^ and DSA^NEG^ recipients. A, viSNE analysis of CD19^+^ B-cell subpopulations (top) labeled by Phenograph cluster and corresponding heatmap assignment (bottom) for all subjects and time points combined (see Materials and Methods). B, Analysis of the percentages of 10 B-cell subpopulations (see Materials and Methods, n = 21 subjects). Error bars represent SEM. Comparisons at all time points were not significantly different (unpaired *t* test). Ab, antibody; Breg, regulatory B cells; DSA, donor-specific antibody; DSA^NEG^, DSA-negative recipients; DSA^POS^, DSA-positive recipients; PBMC, peripheral blood mononuclear cells; SEM, standard error of the mean.](txd-5-e481-g008){#F5}

However, we noticed a trend toward increased B cells with antibody-secreting or memory phenotypes at the time of DSA in DSA^POS^ recipients compared with DSA^NEG^ individuals. We then hypothesized that stratification of DSA^POS^ recipients according to the development of AMR within the first 5 years posttransplant would elucidate cells potentially responsible for this immunological process. B cells with antibody-secreting or memory phenotypes were significantly increased at the time of DSA detection only in DSA^POS^ recipients that later developed AMR (Figure [6](#F6){ref-type="fig"}). Of note, these cells were present in the peripheral blood ≈18 months before the onset of AMR diagnosis by biopsy (Table [2](#T2){ref-type="table"}). None of the major immune compartments differed significantly at any time points between DSA^POS^ patients who did or did not develop AMR. DSA levels at 2 and 3 years after transplant in DSA^POS^ patients who developed AMR did not significantly differ compared with those of DSA^POS^ patients who did not develop AMR (DSA at 2 y: 12 170 ± 7722 vs 8540 ± 7799, *P* = 0.48; at 3 y: 11 970 ± 3997 vs 11 600 ± 7214 MFI; *P* = 0.92, respectively). The 3 patients who lost their grafts developed AMR and had high levels of B cells with antibody-secreting and memory phenotypes.

![B cells with antibody-secreting and memory phenotype were increased at the time of DSA detection only in DSA^POS^ patients who later developed AMR. Analysis of the percentages of antibody-secreting (left) and memory B cell (right) subpopulations stratified by DSA and AMR status (see Materials and Methods, n = 21 subjects). Error bars represent SEM. \**P* \< 0.05, \*\**P* \< 0.01 by ANOVA. Ab, antibody; AMR, antibody-mediated rejection; AMR^NEG^, AMR negative recipients; AMR^POS^, AMR positive; DSA, donor-specific antibody; DSA^POS^, DSA-positive recipients; PBMC, peripheral blood mononuclear cells; SEM, standard error of the mean.](txd-5-e481-g009){#F6}

DISCUSSION
==========

Identifying cellular immune mediators responsible for AMR in kidney transplant recipients has proven difficult due to the limited number of markers that can be probed using flow cytometry. We utilized unbiased CyTOF analyses to comprehensively characterize the immune phenotype in pediatric kidney transplant recipients using serial samples collected before and at the time of DSA development. While CyTOF has been used with great success in the oncologic sciences, its implementation in human solid organ transplantation has been limited to a few studies.^[@R46],[@R56]^ Herein, we discovered that, while percentages of circulating B cells with an antibody-secreting or memory phenotype did not significantly differ between DSA^POS^ and DSA^NEG^ recipients before DSA detection, they were enriched at the time of DSA detection only in recipients who developed AMR \>1 year later.

It is well established that DSA positivity portends inferior allograft outcomes due to the increased risk of AMR.^[@R8],[@R57],[@R58]^ However, the factors leading to dnDSA development and progression to AMR are unclear. Half of the DSA^POS^ recipients in our cohort developed AMR despite similar baseline characteristics, immunosuppression regimens, and donor/recipient HLA matches (Table [1](#T1){ref-type="table"}). Nonadherence has been implied as a major risk factor for the development of DSA, especially in pediatric recipients.^[@R43],[@R44]^ IPV in cyclosporine and tacrolimus levels was within target ranges and similar across all recipients (**Figure S1, SDC**, <http://links.lww.com/TXD/A217>), suggesting that nonadherence was not a major determinant for dnDSA development in our cohort.^[@R42]-[@R44]^

DSA levels at the time of DSA detection were similar as well, making this information of little value to risk-stratify DSA recipients who will develop AMR (**Table S3, SDC**, <http://links.lww.com/TXD/A217>). Others have reported that the ability to fix and activate the complement cascade, as determined by C1q and C3d binding, identifies pathogenic DSA and correlates with shorter allograft survival.^[@R21],[@R23]-[@R27],[@R59],[@R60]^ However, 9 out of the 10 recipients in our cohort had DSA that bound C1q (Table [3](#T3){ref-type="table"}). More DSA^POS^AMR^POS^ recipients had C3d-binding DSA, but this trend did not reach statistical significance (*P* = 0.52). Therefore, in this pediatric population, C1q and C3d staining did not prove to be useful predictors of AMR development.

B cells with memory or antibody-secreting phenotype were the only cell subsets that we identified as differentially increased in DSA^POS^ recipients that later developed AMR. These cells were identified based on their absence of IgD and expression of CD27---signifying mature B cells^[@R61]^---and differential expression of CD38. CD38 is a highly conserved type II glycoprotein that possesses pleiotropic effects on B-cell function and maturation.^[@R62]-[@R64]^ Whereas CD38 induces apoptosis in early B cells, it promotes survival in germinal center B cells.^[@R65]^ Antibody-secreting cells, including plasma cells and immature plasmablasts,^[@R66]^ express high levels of CD38, whereas memory B cells, a long-lasting B-cell subset capable of differentiating into antibody-secreting B cells and producing high-affinity antibodies upon antigen re-encounter,^[@R33]-[@R35]^ lack CD38 expression.^[@R67],[@R68]^ Our data confirm and expand to a pediatric population previous evidence by Luque et al^[@R52]^ showing increased donor-reactive memory B cells in the circulation of adult DSA^POS^ recipients with ongoing AMR. Intriguingly, these authors identified donor-reactive memory B cells by Elispot, while they failed to identify a difference in any of the B cell subsets measured by flow cytometry.^[@R52]^ The increased sensitivity of the CyTOF technique when compared with flow cytometry provides the opportunity to identify and quantify low-frequency lymphocyte populations in peripheral blood. Indeed, we were able to probe for differences in 9 major immune compartments and 25 lymphocyte subpopulations using CyTOF.

Our comprehensive immune phenotypic characterization by CyTOF also allowed us to test for any relationship between circulating T-cell subsets and DSA development. Unexpectedly, we did not detect differences in any of the CD4^+^ or CD8^+^ T-cell subsets between DSA^POS^ and DSA^NEG^ recipients at any time point, including circulating T~FH~---a specialized T-cell subset integral to efficient antibody production that assists B-cell differentiation into plasma cells---and T~REG~. Different groups have attempted to find a relationship between circulating T~FH~ or T~REG~ and graft outcomes, but results, invariably generated using flow cytometry, have been inconsistent so far.^[@R52],[@R69]-[@R72]^ Our comprehensive, unbiased approach on serially collected samples does not support such a relationship, at least in pediatric patients.

Our study has some limitations. The sample size was relatively small, and we did not validate our results in an independent cohort. However, we resampled and reanalyzed the B-cell clusters 5 times to ensure that our findings were statistically robust. CyTOF allowed us to conduct comprehensive immune phenotyping with increased sensitivity for low-expressed markers. Although perfectly suited to extract the most information from a reduced number of samples, it cannot overcome the limitations associated with a small number of patients. We also have not determined that the B cells with a memory or antibody-secreting phenotype are specific to the HLA antigens that the DSAs were against. Lack of functional data on B cells with a memory or antibody-secreting phenotype represents another limitation, although the cell surface markers used to classify these cells are well established in the literature.^[@R67],[@R68]^ Our phenotypic data complement functional studies by others showing that memory B cells can be detected in the circulation before DSA development.^[@R52]^ Future studies will be required to define antigen specificity of B cells with memory or antibody-secreting phenotype.

Overall, the present study demonstrates that circulating B cells with an antibody-secreting and memory phenotype increase in DSA^POS^ recipients before the development of AMR. We also show that these cells are detectable in the peripheral circulation at the time of DSA onset, more than a year before biopsy-proven rejection, highlighting a possible role for aggressive B-cell--targeted immunosuppression in these at-risk recipients. These pilot results warrant further validation in larger cohort studies.
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